NAD+ Peptide Complex
Also known as: NAD+, Nicotinamide Adenine Dinucleotide
Overview
While NAD+ (nicotinamide adenine dinucleotide) is technically a coenzyme rather than a peptide, it is a central component of peptide therapy protocols targeting mitochondrial function and aging. NAD+ levels decline 50%+ with aging, contributing to mitochondrial dysfunction, reduced DNA repair, and epigenetic aging. IV NAD+ therapy and oral NAD+ precursors (NMN, NR) are widely used alongside mitochondrial peptides (SS-31, MOTS-c) and NNMT inhibitors (5-Amino-1MQ) in comprehensive anti-aging protocols.
Mechanism of Action
NAD+ serves as a cofactor for: sirtuins (SIRT1-7) regulating gene expression, DNA repair, and metabolism; poly(ADP-ribose) polymerases (PARPs) for DNA damage repair; CD38/CD157 ectoenzymes regulating calcium signaling; and the electron transport chain for ATP synthesis. Restoration of NAD+ reactivates these pathways. When combined with NNMT inhibitors like 5-Amino-1MQ, the combination addresses both supply (NAD+ therapy) and conservation (NNMT inhibition) for sustained cellular effects.
Potential Benefits
- Restoration of mitochondrial electron transport chain efficiency
- Reactivation of SIRT1-7 longevity pathways
- Enhanced DNA repair capacity via PARP reactivation
- Improved cellular energy metabolism
- Synergistic with MOTS-c, SS-31, and 5-Amino-1MQ in anti-aging stacks
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Typical Range | 250-1000 mg/day oral precursors; 100-1000 mg IV NAD+ |
| Beginner | 250-500 mg NMN or NR orally daily |
| Intermediate | 500-1000 mg NMN daily; or 250-500 mg IV weekly |
| Advanced | 1000 mg IV NAD+ 1-3x/week; high-dose NMN/NR orally |
| Cycle Duration | Continuous oral; IV typically 4-8 week courses |
| Cycle Off | IV courses: 4-8 weeks off; oral precursors may be continued indefinitely |
IV NAD+ provides the most direct cellular repletion. IV administration often causes mild flushing, chest tightness, or nausea during infusion — slow administration rate resolves this. NAD+ levels naturally decline ~50% by age 50.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Oral Moderate
NMN and NR are oral precursors that raise cellular NAD+; convenient and cost-effective vs IV; NMN may convert to NR in gut prior to absorption
Subcutaneous Injection High
Direct NAD+ injection; increasingly used as alternative to IV infusion; practical and cost-effective for home use
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving NAD+ Peptide Complex:
Mitochondrial Longevity Stack
Complete mitochondrial optimization for longevity and metabolic health
NAD+ provides cofactor substrate for sirtuins and PARP; MOTS-c drives AMPK/biogenesis; SS-31 protects cristae; Humanin prevents apoptosis.
Anti-Aging Foundation Stack
Comprehensive anti-aging targeting cellular, epigenetic, and tissue aging
One of the most complete longevity stacks; addresses multiple hallmarks of aging simultaneously.
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Typical Vial Size | 500mg/50ml IV solution, 100mg injectable vials, 250mg/500mg oral capsules |
|---|---|
| BAC Water | IV solutions in saline; injectable vials use sterile water |
| Storage | Refrigerate IV/injectable formulations at 2-8°C; oral capsules at room temperature |
| Shelf Life | 24 months sealed; follow manufacturer guidance for opened formulations |
Need exact syringe measurements?
Amino Acid Sequence
N/A (coenzyme, not a peptide)
Side Effects & Safety
- IV NAD+: flushing, nausea, chest tightness during infusion (temporary)
- Oral precursors: generally well-tolerated
Synergistic Compounds
The following compounds have been studied alongside NAD+ Peptide Complex for potential complementary or synergistic effects:
Learn More
References & Further Reading
- [object Object]